{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:11:46Z","timestamp":1793211106347,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s12185-025-03979-1","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T17:29:35Z","timestamp":1744046975000},"page":"148-152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Histological confirmation and radiotherapy facilitate continuation of epcoritamab in a patient with tumor flare reaction"],"prefix":"10.1007","volume":"122","author":[{"given":"Mai","family":"Fujita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Jinnouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Mihashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kidoguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Kusaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Itamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Katsuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,29]]},"reference":[{"key":"3979_CR1","doi-asserted-by":"crossref","unstructured":"Poletto S, Novo M, Paruzzo L, Frascione PMM, Vitolo U. Treatment strategies for patients with diffuse large B-cell lymphoma. Cancer Treat Rev W.B. Saunders. 2022:02443.","DOI":"10.1016\/j.ctrv.2022.102443"},{"key":"3979_CR2","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","volume":"41","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J Clin Oncol. 2023;41:2238\u201347.","journal-title":"J Clin Oncol"},{"key":"3979_CR3","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1182\/blood.2023022432","volume":"143","author":"JL Crombie","year":"2024","unstructured":"Crombie JL, Graff T, Falchi L, Karimi YH, Bannerji R, Nastoupil L, et al. Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy. Blood. 2024;143:1565\u201375.","journal-title":"Blood"},{"key":"3979_CR4","doi-asserted-by":"publisher","first-page":"S157","DOI":"10.1016\/j.jtct.2023.12.200","volume":"30","author":"W Bahaj","year":"2024","unstructured":"Bahaj W, Hegazi M, Emmons R. Unveiling immediate pseudo-progression with epcoritamab in lymphoma treatment: case series exploration. Transplant Cell Ther. 2024;30:S157.","journal-title":"Transplant Cell Ther"},{"key":"3979_CR5","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.bbmt.2019.02.008","volume":"25","author":"J Wang","year":"2019","unstructured":"Wang J, Hu Y, Yang S, Wei G, Zhao X, Wu W, et al. Role of fluorodeoxyglucose positron emission tomography\/computed tomography in predicting the adverse effects of chimeric antigen receptor T cell therapy in patients with Non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2019;25:1092\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3979_CR6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/10428194.2022.2161304","volume":"64","author":"C Sortais","year":"2023","unstructured":"Sortais C, Cordeil S, Bourbon E, Idlhaj M, Ferrant E, Safar V, et al. Flare-up phenomenon or pseudoprogression after CAR T-cell infusion in non-Hodgkin aggressive lymphomas. Leuk Lymphoma. 2023;64:707\u201311.","journal-title":"Leuk Lymphoma"},{"key":"3979_CR7","doi-asserted-by":"crossref","unstructured":"Li N, Wang G, Hou X, Tai R, Huang S, He Z, et al. Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer. Int Immunopharmacol. 2022;108.","DOI":"10.1016\/j.intimp.2022.108803"},{"key":"3979_CR8","doi-asserted-by":"crossref","unstructured":"Wang GX, Kurra V, Gainor JF, Sullivan RJ, Flaherty KT, Lee SI, et al. Immune checkpoint inhibitor cancer therapy: spectrum of imaging findings. Radiogr a Rev Publ Radiol Soc North Am Inc. 2017;37:2132\u201344.","DOI":"10.1148\/rg.2017170085"},{"key":"3979_CR9","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1097\/CAD.0000000000000814","volume":"30","author":"TB Amina","year":"2019","unstructured":"Amina TB. Tumour flare reaction in cancer treatments: a comprehensive literature review. Anticancer Drugs. 2019;30:953\u20138.","journal-title":"Anticancer Drugs"},{"key":"3979_CR10","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, et al. Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016;128:2489\u201396.","journal-title":"Blood"},{"key":"3979_CR11","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1093\/annonc\/mdq048","volume":"21","author":"RK Hales","year":"2010","unstructured":"Hales RK, Banchereau J, Ribas A, Tarhini AA, Weber JS, Fox BA, et al. Assessing oncologic benefit in clinical trials of immunotherapy agents. Ann Oncol. 2010;21:1944\u201351.","journal-title":"Ann Oncol"},{"key":"3979_CR12","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1182\/bloodadvances.2020001696","volume":"4","author":"CK Rushton","year":"2020","unstructured":"Rushton CK, Arthur SE, Alcaide M, Cheung M, Jiang A, Coyle KM, et al. Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma. Blood Adv. 2020;4:2886\u201398.","journal-title":"Blood Adv"},{"key":"3979_CR13","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1182\/blood.2023022348","volume":"143","author":"SJ Schuster","year":"2024","unstructured":"Schuster SJ, Huw L-Y, Bolen CR, Maximov V, Polson AG, Hatzi K, et al. Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed\/refractory B-cell lymphomas. Blood. 2024;143:822\u201332.","journal-title":"Blood"},{"key":"3979_CR14","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.3390\/jcm12103498","volume":"12","author":"F Tutino","year":"2023","unstructured":"Tutino F, Giovannini E, Chiola S, Giovacchini G, Ciarmiello A. Assessment of response to immunotherapy in patients with Hodgkin lymphoma: towards quantifying changes in tumor burden using FDG-PET\/CT. J Clin Med. 2023;12:3498.","journal-title":"J Clin Med"},{"key":"3979_CR15","doi-asserted-by":"crossref","unstructured":"G\u00e9raud A, Hueso T, Laparra A, Bige N, Ouali K, Cauquil C, et al. Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review. Eur J Cancer. 2024;205.","DOI":"10.1016\/j.ejca.2024.114075"},{"key":"3979_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40425-016-0156-7","volume":"4","author":"J Kang","year":"2016","unstructured":"Kang J, Demaria S, Formenti S. Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother cancer. 2016;4:51.","journal-title":"J Immunother cancer"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03979-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-03979-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03979-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T11:17:39Z","timestamp":1750936659000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-03979-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,29]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3979"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-03979-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,29]]},"assertion":[{"value":"25 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SK has received honoraria from Pfizer, Otsuka and Novartis Pharmaceuticals, and research funding from Pfizer, Novartis, Otsuka and Bristol-Myers-Suquibb Pharmaceuticals. The other authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}